NCT05303493View on ClinicalTrials.gov

Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 29, 2022

Primary Completion Date

July 15, 2025

Study Completion Date

July 15, 2025

Conditions
NSCLC Stage IVMelanoma Stage IVUnresectable MelanomaAdvanced Non-Small Cell Lung Cancer
Interventions
BIOLOGICAL

Camu Camu Capsules (Camu Camu powder encapsulated (500mg each) + ICI

Evaluate the safety and tolerability of CC prebiotic in addition to ICI in patients with NSCLC and melanoma

Trial Locations (3)

J4V 2H2

CISSS de la Montérégie-Centre- Hôpital Charles-Le Moyne, Longueuil

H2X 3E4

Centre hospitalier de l'Université de Montréal (CHUM), Montreal

H3T 1E2

Jewish General Hospital, Montreal

All Listed Sponsors
lead

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER